Business Context and Reporting Period
This Form 8-K was filed by Chipotle Mexican Grill, Inc. on August 4, 2026, reporting events occurring as of that date. The filing addresses a public health investigation involving a salmonella outbreak in the supply chain affecting multiple food service retailers in Minnesota and other states.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on a regulatory disclosure regarding a health and safety incident.
Material Changes and Operational Impact
- Investigation Status: Public health authorities, including the FDA and Minnesota Department of Health, are investigating a salmonella outbreak. The Minnesota Department of Health confirmed no ongoing concerns with Chipotle specifically.
- Operational Response: Chipotle identified jalapeños from a specific lot as a potential common ingredient. As a precautionary measure, the company proactively removed these jalapeños from all restaurants and replaced them with product from different growers.
- Cooperation: The company is actively cooperating with public health authorities and has utilized its ingredient traceability system.
Guidance, Outlook, and Risks
On July 29, 2026, Chipotle issued its earnings release and 2026 outlook. Management explicitly stated that due to the uncertain nature of the salmonella investigation outcomes, the guidance did not include any financial impact from these matters. The primary risk identified is the potential financial and reputational impact of the ongoing investigation, though the company maintains that guest and employee safety is the highest priority.
Investor Verification Checklist
- Verify the scope of the salmonella outbreak and whether it expands beyond the initial Minnesota and multi-state supply chain reports.
- Monitor future earnings releases for any updates on the financial impact of the jalapeño removal and supply chain disruption.
- Confirm the timeline for the resolution of the FDA and state health department investigations.
- Review subsequent 8-K filings for any material changes to the company's 2026 outlook.